Aerie Pharmaceuticals (NSDQ:AERI) said today that it resubmit a New Drug Application for the company’s Rhopressa eye drops. The Irvine, Calif.-based company’s NDA was withdrawn in October last year, after a contract manufacturer was not prepared for its pre-approval inspection.
Aerie’s Rhopressa eye drops specifically target the eye’s trabecular network – the diseased tissue responsible for elevated intraocular pressure in patients with glaucoma.
Get the full story at our sister site, Drug Delivery Business News.